Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bakris

Showing results (561-570 of 738) with videos related to

Pageof 74
Sort By:
Journal of Clinical Hypertension (Greenwich, Conn.)|February 22, 2005
Control of blood pressure and other cardiovascular risk factors at different practice settings: outcomes of care provided to diabetic women compared to menSamy I McFarlane, Jonathan Castro, Jasjeet Kaur, et al.
American Heart Journal|October 11, 2011
EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndromeWilliam B White, George L Bakris, Richard M Bergenstal, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|October 6, 2007
Efficacy and safety of darusentan in patients with resistant hypertension: results from a randomized, double-blind, placebo-controlled dose-ranging studyHenry R Black, George L Bakris, Michael A Weber, et al.
International Journal of Cardiology|February 10, 2009
Association between hyperuricemia and incident heart failure among older adults: a propensity-matched studyO James Ekundayo, Louis J Dell'Italia, Paul W Sanders, et al.
Hypertension (Dallas, Tex. : 1979)|August 3, 2016
Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor AlogliptinWilliam B White, Craig A Wilson, George L Bakris, et al.
Lancet (London, England)|September 21, 2022
Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 TrialDeepak L Bhatt, Muthiah Vaduganathan, David E Kandzari, et al.
Journal of the American Society of Nephrology : JASN|October 24, 2023
Development and Validation of a New Hierarchical Composite End Point for Clinical Trials of Kidney Disease ProgressionHiddo J L Heerspink, Niels Jongs, Patrick Schloemer, et al.
Diabetes, Obesity & Metabolism|October 4, 2022
Finerenone in patients across the spectrum of chronic kidney disease and type 2 diabetes by glucagon-like peptide-1 receptor agonist usePeter Rossing, Rajiv Agarwal, Stefan D Anker, et al.
Journal of the American College of Cardiology|July 13, 2010
Cardiovascular events during differing hypertension therapies in patients with diabetesMichael A Weber, George L Bakris, Kenneth Jamerson, et al.
Archives of Internal Medicine|September 30, 2009
Risk of hyperkalemia in nondiabetic patients with chronic kidney disease receiving antihypertensive therapyJoy M Weinberg, Lawrence J Appel, George Bakris, et al.
Pageof 74

Showing results (561-570 of 738) with videos related to

Sort By:
Pageof 74
Journal of Clinical Hypertension (Greenwich, Conn.)|February 22, 2005
Control of blood pressure and other cardiovascular risk factors at different practice settings: outcomes of care provided to diabetic women compared to menSamy I McFarlane, Jonathan Castro, Jasjeet Kaur, et al.
American Heart Journal|October 11, 2011
EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndromeWilliam B White, George L Bakris, Richard M Bergenstal, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|October 6, 2007
Efficacy and safety of darusentan in patients with resistant hypertension: results from a randomized, double-blind, placebo-controlled dose-ranging studyHenry R Black, George L Bakris, Michael A Weber, et al.
International Journal of Cardiology|February 10, 2009
Association between hyperuricemia and incident heart failure among older adults: a propensity-matched studyO James Ekundayo, Louis J Dell'Italia, Paul W Sanders, et al.
Hypertension (Dallas, Tex. : 1979)|August 3, 2016
Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor AlogliptinWilliam B White, Craig A Wilson, George L Bakris, et al.
Lancet (London, England)|September 21, 2022
Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 TrialDeepak L Bhatt, Muthiah Vaduganathan, David E Kandzari, et al.
Journal of the American Society of Nephrology : JASN|October 24, 2023
Development and Validation of a New Hierarchical Composite End Point for Clinical Trials of Kidney Disease ProgressionHiddo J L Heerspink, Niels Jongs, Patrick Schloemer, et al.
Diabetes, Obesity & Metabolism|October 4, 2022
Finerenone in patients across the spectrum of chronic kidney disease and type 2 diabetes by glucagon-like peptide-1 receptor agonist usePeter Rossing, Rajiv Agarwal, Stefan D Anker, et al.
Journal of the American College of Cardiology|July 13, 2010
Cardiovascular events during differing hypertension therapies in patients with diabetesMichael A Weber, George L Bakris, Kenneth Jamerson, et al.
Archives of Internal Medicine|September 30, 2009
Risk of hyperkalemia in nondiabetic patients with chronic kidney disease receiving antihypertensive therapyJoy M Weinberg, Lawrence J Appel, George Bakris, et al.
Pageof 74